Fresenius to restructure global clinical research services under its Frenova arm

Dialysis machine
Fresenius’ similar research services in Latin America, Europe, the Middle East and Africa will be bundled under Frenova, according to the company. (Getty/porpeller)

Dialysis giant Fresenius Medical Care announced plans to expand its work in international clinical research, elevating its North America-centric Frenova research subsidiary to the global stage.

The contract clinical development services provider Frenova Renal Research will be integrated with Fresenius’ new global medical office, which was established earlier this year to coordinate clinical R&D and practice sharing among its network of dialysis clinics.

The subsidiary develops medicines and medtech offerings in kidney research and conditions related to renal disease—such as anemia, diabetic complications, inflammation and metabolism—as well as in home dialysis and vascular access.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Frenova is active at the intersection of clinical research and patient care,” Frank Maddux, Fresenius’ chief medical officer and head of the global office, said in a statement. “By making this expertise available worldwide, we will enable a faster, more efficient development of medications and other products.”

RELATED: Fresenius makes a flurry of deals in Chinese dialysis clinics and hospitals

In addition, Fresenius’ similar research efforts in Latin America, Europe, the Middle East and Africa will be bundled under Frenova, granting it access to a network of more than 550 researchers in at least 350 locations, according to the company.

Frenova previously collaborated with PPD in nephrology, allowing the global contract research organization to use its F1RST Up coalition of clinical study sites, aimed at patient recruitment and retention.

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Elon Musk pulled back the curtain on his brain interface-developing Neuralink, saying the startup holds the promise of merging people with AI.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.